Nuwaihyd R, Redler S, Heilmann S, Drichel D, Wolf S, Birch P, Dobson K, Lutz G, Giehl KA, Kruse R, Tazi-Ahnini R, Hanneken S, Bhm M, Miesel A, Fischer T, Wolff H, Becker T, Garcia-Bartels N, Blume-Peytavi U, Nthen MM, Messenger AG, Betz RC (2014) Investigation of four novel male androgenetic alopecia susceptibility loci: no association with female pattern hair loss
[DOI] [PubMed] [Google Scholar] 66.Mar-Bauset S., Llopis-Gonzlez A., Zazpe-Garca I., Mar-Sanchis A., Morales-Surez-Varela M
Because Krystexxa is given intravenously, it would be expected that the great majority of its use would be by rheumatologists rather than by internists or primary care physicians
Severe, constant symptoms typically receive higher ratings compared to mild or intermittent symptoms